A new clinical trial has revealed that tirzepatide (Zepbound) surpasses semaglutide (Wegovy) in promoting weight loss among ...

If you’re struggling with weight, you’re not alone. Around 42 percent of American adults have obesity. In addition to ...

When the Food and Drug Administration (FDA) approved Byetta (exenatide) in 2005, doctors thought it was just approving the ...

The findings presented at a conference in Chicago found a slightly lower risk of obesity-related cancers when adults with ...

The report also underscored the importance of maintaining muscle mass and bone density while losing weight. Since weight loss ...

Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep ...

As the Food and Drug Administration clamps down on off-brand weight loss medications, Seattle-area residents are stocking up ...

Novo Nordisk (NVO) makes Ozempic, the best-known GLP-1 drug out today. And until quite recently, the Danish pharma giant ...

Despite her active and healthy lifestyle, Sasha Barden felt stuck in her weight loss journey. She decided to try GLP-1 medications to support her weight loss goal. After six months on Wegovy ...

Viking Therapeutics faces tough obesity drug rivals, with VK2735 showing promise but an uncertain edge. Find out why VKTX ...

The percentage of adults prescribed a GLP-1 drug like Wegovy or Zepbound jumped almost sevenfold over the past five years, ...

The percentage of overweight or obese adults prescribed GLP-1s jumped by almost 587% between 2019 and 2024, according to a ...